Skip to main content

Table 1 (abstract P24). Data on primary and secondary outcomes Safety: Exposure-adjusted Subject Incidence Rates of Treatment-emergent Adverse Events Occurring in > 2/100 subject-years for total erenumab (Safety Analysis Set)

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

Adverse event Erenumab 70 mg/140 mg (N=609), n (%) / e [r]
Viral upper respiratory tract infection 96 (15.8) / 586.0 [16.4]
Upper respiratory tract infection 45 (7.4) / 624.5 [7.2]
Sinusitis 44 (7.2) / 620.4 [7.1]
Arthralgia 27 (4.4) / 636.7 [4.2]
Migraine 26 (4.3) / 638.5 [4.1]
  1. % = n / N x 100; N = number of subjects exposed to erenumab in OLE; n = number of subjects reporting at least 1 occurrence of an adverse event; r = exposure-adjusted subject rate per 100 subject-years (n / e x 100)
  2. e = sum across all subjects, the total time at risk in the study in years